Robert R. Goodwin
Corporate Officer/Principal bei Takeda Vaccines (Montana), Inc.
Profil
Robert R.
Goodwin is currently the VP & Head-Global Norovirus Program at Takeda Vaccines (Montana), Inc. Previously, he held the position of Director-Technology Transfer at the University of Rochester and Director-Business Development at STS Biopolymers, Inc. From 2000 to 2014, he served as the President & Chief Operating Officer at LigoCyte Pharmaceuticals, Inc. Dr. Goodwin obtained his undergraduate degree from the University of Utah and the University of California, Los Angeles.
Aktive Positionen von Robert R. Goodwin
| Unternehmen | Position | Beginn |
|---|---|---|
Takeda Vaccines (Montana), Inc.
 Takeda Vaccines (Montana), Inc. Pharmaceuticals: MajorHealth Technology Takeda Vaccines (Montana), Inc. operates as a biopharmaceutical company which focuses on the development of vaccines that prevent human infectious diseases. It specializes in developing vaccines against norovirus, influenza, and respiratory syncytial virus. The firm develops norovirus VLP vaccines that mimic the surface configuration of the live virus without the ability to cause infection, respiratory syncytial virus vaccine that mediates cell entry in its native form for use in anthrax treatment. The company was founded by Robert F. Bargatze on March 13, 2008 and is headquartered in Bozeman, MT. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Robert R. Goodwin
| Unternehmen | Position | Ende |
|---|---|---|
| LigoCyte Pharmaceuticals, Inc. | Präsident | 16.04.2014 |
STS Biopolymers, Inc.
 STS Biopolymers, Inc. Industrial SpecialtiesProcess Industries Part of Angiotech Pharmaceuticals, Inc., STS Biopolymers, Inc. develops, manufactures, and licenses custom polymer-based coatings for medical devices. The company is based in Henrietta, NY. STS Biopolymers was acquired by Angiotech Pharmaceuticals, Inc. on December 04, 2003 for $23 million. | Corporate Officer/Principal | - |
| Rochester Christian University | Corporate Officer/Principal | - |
Ausbildung von Robert R. Goodwin
| University of Utah | Undergraduate Degree |
| University of California, Los Angeles | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
STS Biopolymers, Inc.
STS Biopolymers, Inc. Industrial SpecialtiesProcess Industries Part of Angiotech Pharmaceuticals, Inc., STS Biopolymers, Inc. develops, manufactures, and licenses custom polymer-based coatings for medical devices. The company is based in Henrietta, NY. STS Biopolymers was acquired by Angiotech Pharmaceuticals, Inc. on December 04, 2003 for $23 million. | Process Industries |
| LigoCyte Pharmaceuticals, Inc. | Health Technology |
Takeda Vaccines (Montana), Inc.
Takeda Vaccines (Montana), Inc. Pharmaceuticals: MajorHealth Technology Takeda Vaccines (Montana), Inc. operates as a biopharmaceutical company which focuses on the development of vaccines that prevent human infectious diseases. It specializes in developing vaccines against norovirus, influenza, and respiratory syncytial virus. The firm develops norovirus VLP vaccines that mimic the surface configuration of the live virus without the ability to cause infection, respiratory syncytial virus vaccine that mediates cell entry in its native form for use in anthrax treatment. The company was founded by Robert F. Bargatze on March 13, 2008 and is headquartered in Bozeman, MT. | Health Technology |
